In this review find out about the controversy with regards to the technical details of portal vein embolization , periprocedural management and whether alternative methods of achieving future liver remnant hypertrophy are preferable.
In this article the authors review outcomes for intrahepatic cholangiocarcinoma patients and explore how identifying factors associated with disease recurrence and survival could help better stratify patients for clinical trials.
This article reviews yttrium-90 radioembolization of hepatocellular carcinoma from a clinical perspective, considering safety and efficacy, patient selection, and optimal assessment and management of patients.
How have transarterial therapies for hepatocellular carcinoma evolved over recent years? What impact have these changes had on patient outcomes? Read more in our partner journal Hepatic Oncology.
This review article from our partner journal Hepatic Oncology explores the immunology of hepatocellular carcinoma and details clinical trials investigating the efficacy of immune checkpoint blockade in the disease.
This review provides a critical summary of the evidence for the utility of ctDNA as a diagnostic and prognostic biomarker in hepatocellular carcinoma – including discussion of the potential utility of circulating tumor cells.
The evolving role of liver transplantation in the management of patients with perihilar cholangiocarcinoma is discussed in this review article from Hepatic Oncology.
Find out more about the current status of hepatocellular carcinoma risk assessment and how it might translate in future into better identification of the at-risk population.
Contrary to its historically perceived inferiority to resection, could there be a bigger role for ablative therapies in the management of patients with hepatocellular carcinoma?
This opinion article sheds light on the potential role of endoplasmic reticulum stress within hepatocytes in obesity-driven hepatocarcinogenesis.
